Sanjivani Paranteral Ltd. (BSE: 531569) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹188 Cr, it ranks #2,690 by market cap among the 6,189 Indian listed companies on FinBizNet, and #12 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹152.80 (as of 26 Oct 2026), the share price is 37.4% below its 52-week high of ₹244.00 and 21.3% above its 52-week low of ₹126.00. The share price is down 24.7% over one year and up 2.8% over three months.
| Current Price | ₹152.80 |
|---|---|
| Market Cap | ₹188 Cr |
| BSE Code | 531569 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 27.5 |
| Return on Equity | 14.76% |
| Return on Assets | 6.73% |
| 52-Week Range | ₹126.00 – ₹244.00 |
| 1-Year Price Change | -24.7% |
| 3-Month Price Change | +2.8% |
| Beta (1Y) | 1.05 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.sanjivani.co.in |
| Revenue | ₹19 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 11.8% |
| EPS (Basic) | ₹1.87 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sanjivani Paranteral Limited operates as a pharmaceutical company in India. The company manufactures pharmaceutical products in the form of oral solids, small volume parenteral, and sterile powder formulations for various therapeutic areas, including central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, and anti-allergic. It also offers soft gels, such as multivitamins; topicals comprising corticosteroids, antiseptics, NSAIDs, and anti-bacterial; nasal sprays; liquid and dry powder injections covering antibiotics, anti-emetic, NSAID and analgesic, antimalarial, and proton pump inhibitor and H2 receptor antagonist; capsules and tablets, including antibiotic, antifungal, anticonvulsant, multivitamins, and NSAID and analgesic; dry syrups; and ear/eye drops. In addition, the company exports its products. Sanjivani Paranteral Limited was incorporated in 1994 and is headquartered in Mumbai, India.
1. Manufacturing Pharmaceutical Products-This segment offers oral solids, parenterals, and sterile powder formulations. It also provides contract research and manufacturing services.
1. Pharmaceutical-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,70,481 Cr | 70.1 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹18,748 Cr | 85.4 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹15,350 Cr | 27.2 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,443 Cr | 42.6 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹2,951 Cr | -363.4 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,040 Cr | 105.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹508 Cr | 25.2 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹486 Cr | 24.9 | — | — | +39.4% |
| Sanjivani Paranteral Ltd. | ₹188 Cr | 27.5 | 14.76% | ₹19 Cr | -24.7% |
Listed by market capitalisation. Ratios are shown for context only.
Sanjivani Paranteral Ltd. is trading at ₹152.80, with a market capitalisation of ₹188 Cr.
Sanjivani Paranteral Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Sanjivani Paranteral Ltd. has a P/E of 27.5 and a return on equity of 14.76%.
Sanjivani Paranteral Ltd. is listed on the BSE under the scrip code 531569.
Sanjivani Paranteral Ltd.'s share price is down 24.7% over one year and up 2.8% over three months. Its 52-week range is ₹126.00 to ₹244.00.
In Q1 FY27, Sanjivani Paranteral Ltd. reported revenue of ₹19 Cr and net profit of ₹2 Cr, with basic EPS of ₹1.87 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.